<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02288338</url>
  </required_header>
  <id_info>
    <org_study_id>152DDI14016</org_study_id>
    <nct_id>NCT02288338</nct_id>
  </id_info>
  <brief_title>CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers</brief_title>
  <official_title>CKD-391 in Healthy Volunteers to Investigate the Pharmacokinetic Drug Interaction Between Atorvastatin an Ezetimibe After Oral Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized open-label, multiple dose, three-treatment, three-period, six-sequence,
      crossover study to investigate the pharmacokinetic drug interaction between Atorvastatin and
      Ezetimibe after oral administration in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outcome Measures

        1. Primary endpoint AUCτ,ss, Cmax,ss of atorvastatin and free ezetimibe

        2. Second endpoint 1) AUCinf,ss, Cavg,ss, %fluctuation, tmax,ss, t1/2, CL/Fss, Vd/Fss of
           atorvastatin and free ezetimibe 2) AUCτ,ss, AUCinf,ss, Cmax,ss, tmax,ss, t1/2, metabolic
           ratio of 2-hydroxy atorvastatin and free ezetimibe
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss of atorvastatin and free ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of atorvastatin and free ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf,ss of atorvastatin and free ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg,ss of atorvastatin and free ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%fluctuation of atorvastatin and free ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss of atorvastatin and free ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of atorvastatin and free ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/Fss of atorvastatin and free ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/Fss of atorvastatin and free ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss of 2-hydroxy atorvastatin and total ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf,ss of 2-hydroxy atorvastatin and total ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss of 2-hydroxy atorvastatin and total ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss of 2-hydroxy atorvastatin and total ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of 2-hydroxy atorvastatin and total ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic ratio of 2-hydroxy atorvastatin and total ezetimibe</measure>
    <time_frame>common : just before the IP administration of D5(D22, D39), D6(D23, D40)</time_frame>
    <description>Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1(Lipitor®&gt;Ezetrol®&gt;Lipitor®, Ezetrol®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment
atorvastatin calcium 40mg will be administration to healthy volunteers during 7days
after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days
after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2(Ezetrol®&gt;Lipitor®, Ezetrol®&gt;Lipitor®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment
ezetimibe 10mg will be administered to healthy volunteers during 7days
after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days
after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3(Lipitor®, Ezetrol®&gt;Lipitor®&gt;Ezetrol®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment
atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days
after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days
after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4(Lipitor®&gt;Lipitor®, Ezetrol®&gt;Ezetrol®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin calcium 40mg will be administered to healthy volunteers during 7days
after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days
after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5(Ezetrol®&gt;Lipitor®&gt;Lipitor®, Ezetrol®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ezetimibe 10mg will be administered to healthy volunteers during 7days
after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days
after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6(Lipitor®, Ezetrol®&gt;Ezetrol®&gt;Lipitor®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days
after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days
after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 (Lipitor®)</intervention_name>
    <description>atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>1(Lipitor®&gt;Ezetrol®&gt;Lipitor®, Ezetrol®)</arm_group_label>
    <other_name>Lipitor® 40mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 (Ezetrol®)</intervention_name>
    <description>After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>1(Lipitor®&gt;Ezetrol®&gt;Lipitor®, Ezetrol®)</arm_group_label>
    <other_name>Ezetrol® 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 (Lipitor®, Ezetrol®)</intervention_name>
    <description>After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>1(Lipitor®&gt;Ezetrol®&gt;Lipitor®, Ezetrol®)</arm_group_label>
    <other_name>Lipitor® 40mg, Ezetrol® 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 (Ezetrol®)</intervention_name>
    <description>ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>2(Ezetrol®&gt;Lipitor®, Ezetrol®&gt;Lipitor®)</arm_group_label>
    <other_name>Ezetrol® 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2(Lipitor®, Ezetrol®)</intervention_name>
    <description>After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>2(Ezetrol®&gt;Lipitor®, Ezetrol®&gt;Lipitor®)</arm_group_label>
    <other_name>Lipitor® 40mg, Ezetrol® 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 (Lipitor®)</intervention_name>
    <description>After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>2(Ezetrol®&gt;Lipitor®, Ezetrol®&gt;Lipitor®)</arm_group_label>
    <other_name>Lipitor® 40mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3(Lipitor®, Ezetrol®)</intervention_name>
    <description>atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>3(Lipitor®, Ezetrol®&gt;Lipitor®&gt;Ezetrol®)</arm_group_label>
    <other_name>Lipitor® 40mg, Ezetrol® 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 (Lipitor®)</intervention_name>
    <description>After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>3(Lipitor®, Ezetrol®&gt;Lipitor®&gt;Ezetrol®)</arm_group_label>
    <other_name>Lipitor® 40mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 (Ezetrol®)</intervention_name>
    <description>After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>3(Lipitor®, Ezetrol®&gt;Lipitor®&gt;Ezetrol®)</arm_group_label>
    <other_name>Ezetrol® 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 (Lipitor®)</intervention_name>
    <description>atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>4(Lipitor®&gt;Lipitor®, Ezetrol®&gt;Ezetrol®)</arm_group_label>
    <other_name>Lipitor® 40mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4(Lipitor®, Ezetrol®)</intervention_name>
    <description>After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>4(Lipitor®&gt;Lipitor®, Ezetrol®&gt;Ezetrol®)</arm_group_label>
    <other_name>Lipitor® 40mg, Ezetrol® 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 (Ezetrol®)</intervention_name>
    <description>After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>4(Lipitor®&gt;Lipitor®, Ezetrol®&gt;Ezetrol®)</arm_group_label>
    <other_name>Ezetrol® 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 (Ezetrol®)</intervention_name>
    <description>ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>5(Ezetrol®&gt;Lipitor®&gt;Lipitor®, Ezetrol®)</arm_group_label>
    <other_name>Ezetrol® 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 (Lipitor®)</intervention_name>
    <description>After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>5(Ezetrol®&gt;Lipitor®&gt;Lipitor®, Ezetrol®)</arm_group_label>
    <other_name>Lipitor® 40mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 (Lipitor®, Ezetrol®)</intervention_name>
    <description>After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>5(Ezetrol®&gt;Lipitor®&gt;Lipitor®, Ezetrol®)</arm_group_label>
    <other_name>Lipitor® 40mg, Ezetrol® 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6(Lipitor®, Ezetrol®)</intervention_name>
    <description>atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>6(Lipitor®, Ezetrol®&gt;Ezetrol®&gt;Lipitor®)</arm_group_label>
    <other_name>Lipitor® 40mg, Ezetrol® 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6 (Ezetrol®)</intervention_name>
    <description>After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>6(Lipitor®, Ezetrol®&gt;Ezetrol®&gt;Lipitor®)</arm_group_label>
    <other_name>Ezetrol® 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6 (Lipitor®)</intervention_name>
    <description>After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days</description>
    <arm_group_label>6(Lipitor®, Ezetrol®&gt;Ezetrol®&gt;Lipitor®)</arm_group_label>
    <other_name>Lipitor® 40mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age Eligible for Study : 19 Years to 45 Years

          2. If males, Body weight ≥ 55kg, If females, Body weight ≥ 50kg

          3. BSA ≥ 18.5, &lt;25

          4. Accepts healthy volunteers

          5. If female, Negative for pregnancy test at the screening and pre dose of Day 1

          6. The subjects who agree with performing contraception during the study

          7. The subjects who agreed with written informed consent

        Exclusion Criteria:

          1. The subjects with impaired hepatic function, renal function, nervous system etc.

          2. The subjects have a gastrointestinal disease or surgery which can be effected in
             absorption of Investigational product

          3. The subjects with high blood pressure or low blood pressure (Systolic blood
             pressure&gt;150mmHg or &lt;90mmHg, Diastolic blood pressure&gt;100mmHg or &lt;50mmHg

          4. The subjects with abnormal Laboratory test (AST, ALT&gt;1.25 fold of upper normal limit,
             Total bilirubin&gt;1.5 fold of upper normal limit, CPK&gt;2 fold of upper normal limit,
             Estimated Glomerular filtration rate&lt;60mL/min/1.73m2 by Modification of Diet in Renal
             disease formula

          5. The subjects have drug abuse history within 1year or Positive for urine drug test at
             screening

          6. The subjects who took prescription only medicine whch can be effected in metabolism of
             Investigational product within 14days

          7. The subjects who took over the counter drug whch can be effected in metabolism of
             Investigational product within 7days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Soo Park, Ph.D. M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ChongKunDang</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

